RxDoctor Payments Data

Steven Crow, MD

Family Medicine · Lubbock, TXNPI 1740244078

Payments from drug & device makers

$1,336in general payments, 2019–2025

Across 98 payments — averaging $13.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$394
  • AbbVie$203
  • Novo Nordisk$128
  • AstraZeneca$73
  • Merck$69
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$69
  • plus $398 from 15 others

What the payments were for

  • Food & beverage$1,336100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,336 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$322,480
Medicare patients
574
Services billed
9,110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide95$99,284
OzempicSemaglutide69$67,297
EliquisApixaban45$56,482
JanuviaSitagliptin Phosphate37$45,602
TradjentaLinagliptin32$26,520
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$24,574
FarxigaDapagliflozin Propanediol16$23,754
Tresiba Flextouch U-100Insulin Degludec45$21,958
JardianceEmpagliflozin24$20,584
TrulicityDulaglutide17$18,784
XareltoRivaroxaban18$16,703
Lantus SolostarInsulin Glargine,hum.Rec.Anlog80$13,634
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog30$11,221
PremarinEstrogens, Conjugated27$10,179
MyrbetriqMirabegron12$8,590

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30$16$121,937143 claims
Novo NordiskOzempic$128$67,29769 claims
PfizerEliquis, Premarin$58$66,66172 claims
Boehringer IngelheimTradjenta, Jardiance$17$47,10456 claims
MerckJanuvia$69$45,60237 claims
GSKTrelegy Ellipta$394$24,57437 claims
AstraZenecaFarxiga$73$23,75416 claims
Astellas Pharma US IncMyrbetriq$44$8,59012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →